Holen Sie sich die Stockscreener-App
171.61
3.85%
-6.88
Handel nachbörslich:
171.80
0.19
+0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$178.49
Offen:
$175.49
24-Stunden-Volumen:
3.59M
Relative Volume:
1.74
Marktkapitalisierung:
$266.15B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
51.54
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
-12.06%
1M Leistung:
-4.11%
6M Leistung:
+81.31%
1J Leistung:
+138.98%
1-Tages-Spanne:
$171.42
$175.88
1-Wochen-Bereich:
$171.42
$193.79
52-Wochen-Spanne:
$68.61
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
171.61 | 276.82B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,188.58 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 623.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 441.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 308.90B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 295.03B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Why Did AstraZeneca (AZN) Stock Dip More Than the Market Today - Kavout | AI
Astrazeneca (AZN) Stock Dips While Market Gains: Key Facts - Yahoo Finance
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
AstraZeneca's (AZN) Vaccine Influence Under Scrutiny Amid New Ad - GuruFocus
AstraZeneca Selloff Looks Larger Than the Wainua Valuation Damage - Investing.com
AstraZeneca’s Embold Trial Signals a Big Push Into the Obesity Drug Race - TipRanks
Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain - Benzinga
AstraZeneca PLC Stock (AZN) Moved Down by 3.50% on Jul 10: Key Drivers Unveiled - TradingKey
AZN slides over 3% as Wainua Phase III clinical trial fails to meet efficacy goals - Traders Union
ASTRAZENECA : Deutsche Bank reaffirms its Sell rating - marketscreener.com
AstraZeneca: An unexpected late-stage failure doesn't derail Astra - marketscreener.com
AstraZeneca Stock Tumbles 6% Following Late-Stage Heart Disease Drug Trial Failure - TIKR.com
ASTRAZENECA : Bernstein keeps its Buy rating - marketscreener.com
AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN) - PR Newswire
Sino and AstraZeneca sign licence agreement for TQC3721 - Pharmaceutical Technology
AstraZeneca PLC (AZN) Shares Fall 5.7% -- What GF Score of 82 Te - GuruFocus
Fed. Circ. Affirms AstraZeneca Win Over $107.5M Verdict - Law360
AstraZeneca (AZN) Wins Patent Dispute Over Tagrisso - GuruFocus
AstraZeneca wins appeal in Pfizer patent dispute over Tagrisso By Investing.com - Investing.com Nigeria
AstraZeneca Extends Anifrolumab Access With New ROSY-S Rollover Study - TipRanks
FTSE 100 held back by AstraZeneca trial setback - Yahoo Finance UK
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains - marketscreener.com
AstraZeneca slips Thursday, underperforms market - MarketWatch
Micron Surges on AI Chip Report, Meta and AstraZeneca Dip - StartupHub.ai
AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure - Clinical Trials Arena
UK Stocks Drop as AstraZeneca's Heart Drug Trial Results, Geopolitical Tensions Weigh - marketscreener.com
AstraZeneca shares dive on rare trial failure of heart drug - The Malaysian Reserve
AstraZeneca PLC Stock (AZN) Moved Down by 6.72% on Jul 9: A Full Analysis - TradingKey
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study - Yahoo Finance
AstraZeneca Shares Dive on Rare Trial Failure of Heart Drug - Bloomberg.com
ASTRAZENECA : Jefferies keeps its Buy rating - marketscreener.com
AstraZeneca, Ionis Shares Slide After Wainua Misses Target in Heart Disease Trial - WSJ
AstraZeneca's Wainua failure hurts credibility more than valuation, Jefferies warns - Proactive Investors
AstraZeneca stock holds steady on its global pipeline - Ad-hoc-news.de
ASTRAZENECA : Bernstein remains its Buy rating - marketscreener.com
AstraZeneca (AZN) Stock Plunges 9% as Wainua Trial Misses Primary Endpoint - Blockonomi
Breakfast News: AstraZeneca's Heart Drug Flatlines - The Motley Fool
AstraZeneca, Ionis drug fails big heart disease study in major setback - BioPharma Dive
Why Is Ionis Pharmaceuticals, AstraZeneca Stock Tumbling Today?AstraZeneca (NYSE:AZN), Ionis Pharmaceu - Benzinga
AstraZeneca Cardiomyopathy Drug Wainua Fails to Meet Late-Stage Clinical Trial Goal as Shares Plunge Over 8% Pre-Market. - TradingKey
AstraZeneca stock drops 9% after Wainua heart drug trial fails - Yahoo Finance
London's FTSE 100 slips as Middle East tensions persist, AstraZeneca drags - marketscreener.com
AstraZeneca licenses Sino's COPD drug for $2.1bn - BioXconomy
ASTRAZENECA : Buy rating from Goldman Sachs - marketscreener.com
AstraZeneca sees stock market value slump by more than £20bn after drug setback - Yahoo Finance UK
AstraZeneca plc focuses on long-term growth. Oncology and vaccines underpin its strategy - Ad-hoc-news.de
Wainua heart trial misses primary endpoint for AstraZeneca (NYSE: AZN) - Stock Titan
ASTRAZENECA : Buy rating from Jefferies - marketscreener.com
ASTRAZENECA : JP Morgan reiterates its Buy rating - marketscreener.com
AstraZeneca (AZN) Shares Plunge Following Trial Setback - GuruFocus
AstraZeneca Shares Slide After Heart Drug Trial Misses Primary Endpoint - Yahoo Finance UK
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):